Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Syndax Pharmaceuticals IncSNDX · Entity 4578 | SVP, Chief Medical Officer | February 02, 2022 | February 03, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Syndax Pharmaceuticals Inc
Report date February 02, 2022 · Filed February 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 23,280 |
Reported balance
After 2022-01-31 transaction · row 1
1 source rowRow 1 · 2022-01-31 · Other · Acquired 1,714 · Balance 23,280 F1: The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 1,715 shares by the Reporting Person on 1/31/22 pursuant to the Issuer's Employee Stock Purchase Plan. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.79 · Expires 2032-02-02 | Direct | 17,350 |
Reported balance
After 2022-02-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-02-02 · Grant · Acquired 17,350 · Balance 17,350 F2: 1/23rd of the shares subject to the option shall vest monthly over a two-year period. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 1,715 shares by the Reporting Person on 1/31/22 pursuant to the Issuer's Employee Stock Purchase Plan.
F2: 1/23rd of the shares subject to the option shall vest monthly over a two-year period.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Nuvalent, Inc.
Report date July 15, 2026 · Filed July 15, 2026
Section 16 reporting ended · disclosed 2026-07-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 1
1 source rowRow 1 · 2026-07-15 · Other · Disposed 5,146 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated June 9, 2026 (the "Merger Agreement"), by and among (i) Nuvalent, Inc., a Delaware corporation (the "Company"), (ii) GlaxoSmithKline LLC, a Delaware limited liability company ("Parent"), (iii) Harmony Row Acquisition Co., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"), and (iv) solely for purposes of Section 9.14 therein, GSK plc, a public limited company organized under the laws of England and Wales ("Ultimate Parent"), Purchaser completed a tender offer (the "Offer") to purchase all outstanding shares of Class A Common Stock of the Company and Class B Common Stock of the Company. The shares of Class A Common Stock of the Company and Class B Common Stock of the Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for $124.00 per share, net to the seller in cash, without interest (the "Offer Price"), subject to applicable withholding tax. F2: (Continued from footnote 1) After completion of the Offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. |
| Class A Common Stock - Restricted Stock UnitsSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 2
1 source rowRow 2 · 2026-07-15 · Disposition to issuer · Disposed 3,444 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of Class A Common Stock of the Company. F4: Pursuant to the Merger Agreement, each restricted stock unit that was subject solely to time-based vesting (a "Company RSU") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to (or deliverable under) such Company RSU immediately prior to the effective time of the Merger and (y) the Offer Price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.89 · Expires 2031-04-29 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-15 · Disposition to issuer · Disposed 8,361 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Common Stock (a "Company Stock Option") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the effective time of the Merger and (y) the excess, if any, of the Offer Price over the applicable exercise price per share under such Company Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.48 · Expires 2032-10-04 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-07-15 · Disposition to issuer · Disposed 40,000 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Common Stock (a "Company Stock Option") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the effective time of the Merger and (y) the excess, if any, of the Offer Price over the applicable exercise price per share under such Company Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.68 · Expires 2033-06-15 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-07-15 · Disposition to issuer · Disposed 15,000 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Common Stock (a "Company Stock Option") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the effective time of the Merger and (y) the excess, if any, of the Offer Price over the applicable exercise price per share under such Company Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $80.03 · Expires 2034-06-12 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-07-15 · Disposition to issuer · Disposed 3,789 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Common Stock (a "Company Stock Option") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the effective time of the Merger and (y) the excess, if any, of the Offer Price over the applicable exercise price per share under such Company Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $75.53 · Expires 2035-06-18 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-07-15 · Disposition to issuer · Disposed 4,147 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Common Stock (a "Company Stock Option") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the effective time of the Merger and (y) the excess, if any, of the Offer Price over the applicable exercise price per share under such Company Stock Option. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated June 9, 2026 (the "Merger Agreement"), by and among (i) Nuvalent, Inc., a Delaware corporation (the "Company"), (ii) GlaxoSmithKline LLC, a Delaware limited liability company ("Parent"), (iii) Harmony Row Acquisition Co., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"), and (iv) solely for purposes of Section 9.14 therein, GSK plc, a public limited company organized under the laws of England and Wales ("Ultimate Parent"), Purchaser completed a tender offer (the "Offer") to purchase all outstanding shares of Class A Common Stock of the Company and Class B Common Stock of the Company. The shares of Class A Common Stock of the Company and Class B Common Stock of the Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for $124.00 per share, net to the seller in cash, without interest (the "Offer Price"), subject to applicable withholding tax.
F2: (Continued from footnote 1) After completion of the Offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent.
F3: Each restricted stock unit represents a contingent right to receive one share of Class A Common Stock of the Company.
F4: Pursuant to the Merger Agreement, each restricted stock unit that was subject solely to time-based vesting (a "Company RSU") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to (or deliverable under) such Company RSU immediately prior to the effective time of the Merger and (y) the Offer Price.
F5: Pursuant to the Merger Agreement, each option to purchase shares of Common Stock (a "Company Stock Option") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the effective time of the Merger and (y) the excess, if any, of the Offer Price over the applicable exercise price per share under such Company Stock Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 15, 2026 Filed Jul 15, 2026 23:11 UTC | Nuvalent, Inc. NUVL · Entity 29892 | Disposition to issuerStock Option (Right to Buy) · Derivative | 4,147 | Not disclosed Strike: $75.53 | Not disclosed |
DisclosureSEC source: 0001193125-26-305095 · ownership.xml · derivative · entry 7 Meyers Michael L. · CIK 0001664204 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 4,147 shares Expires 2035-06-18 F5 · price: Pursuant to the Merger Agreement, each option to purchase shares of Common Stock (a "Company Stock Option") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the effective time of the Merger and (y) the excess, if any, of the Offer Price over the applicable exercise price per share under such Company Stock Option. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Common Stock (a "Company Stock Option") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the effective time of the Merger and (y) the excess, if any, of the Offer Price over the applicable exercise price per share under such Company Stock Option. Read SEC document |
| July 15, 2026 Filed Jul 15, 2026 23:11 UTC | Nuvalent, Inc. NUVL · Entity 29892 | Disposition to issuerStock Option (Right to Buy) · Derivative | 3,789 | Not disclosed Strike: $80.03 | Not disclosed |
DisclosureSEC source: 0001193125-26-305095 · ownership.xml · derivative · entry 6 Meyers Michael L. · CIK 0001664204 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 3,789 shares Expires 2034-06-12 F5 · price: Pursuant to the Merger Agreement, each option to purchase shares of Common Stock (a "Company Stock Option") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the effective time of the Merger and (y) the excess, if any, of the Offer Price over the applicable exercise price per share under such Company Stock Option. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Common Stock (a "Company Stock Option") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the effective time of the Merger and (y) the excess, if any, of the Offer Price over the applicable exercise price per share under such Company Stock Option. Read SEC document |
| July 15, 2026 Filed Jul 15, 2026 23:11 UTC | Nuvalent, Inc. NUVL · Entity 29892 | Disposition to issuerStock Option (Right to Buy) · Derivative | 15,000 | Not disclosed Strike: $44.68 | Not disclosed |
DisclosureSEC source: 0001193125-26-305095 · ownership.xml · derivative · entry 5 Meyers Michael L. · CIK 0001664204 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 15,000 shares Expires 2033-06-15 F5 · price: Pursuant to the Merger Agreement, each option to purchase shares of Common Stock (a "Company Stock Option") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the effective time of the Merger and (y) the excess, if any, of the Offer Price over the applicable exercise price per share under such Company Stock Option. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Common Stock (a "Company Stock Option") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the effective time of the Merger and (y) the excess, if any, of the Offer Price over the applicable exercise price per share under such Company Stock Option. Read SEC document |
| July 15, 2026 Filed Jul 15, 2026 23:11 UTC | Nuvalent, Inc. NUVL · Entity 29892 | Disposition to issuerStock Option (Right to Buy) · Derivative | 40,000 | Not disclosed Strike: $19.48 | Not disclosed |
DisclosureSEC source: 0001193125-26-305095 · ownership.xml · derivative · entry 4 Meyers Michael L. · CIK 0001664204 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 40,000 shares Expires 2032-10-04 F5 · price: Pursuant to the Merger Agreement, each option to purchase shares of Common Stock (a "Company Stock Option") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the effective time of the Merger and (y) the excess, if any, of the Offer Price over the applicable exercise price per share under such Company Stock Option. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Common Stock (a "Company Stock Option") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the effective time of the Merger and (y) the excess, if any, of the Offer Price over the applicable exercise price per share under such Company Stock Option. Read SEC document |
| July 15, 2026 Filed Jul 15, 2026 23:11 UTC | Nuvalent, Inc. NUVL · Entity 29892 | Disposition to issuerStock Option (Right to Buy) · Derivative | 8,361 | Not disclosed Strike: $6.89 | Not disclosed |
DisclosureSEC source: 0001193125-26-305095 · ownership.xml · derivative · entry 3 Meyers Michael L. · CIK 0001664204 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 8,361 shares Expires 2031-04-29 F5 · price: Pursuant to the Merger Agreement, each option to purchase shares of Common Stock (a "Company Stock Option") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the effective time of the Merger and (y) the excess, if any, of the Offer Price over the applicable exercise price per share under such Company Stock Option. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Common Stock (a "Company Stock Option") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the effective time of the Merger and (y) the excess, if any, of the Offer Price over the applicable exercise price per share under such Company Stock Option. Read SEC document |
| July 15, 2026 Filed Jul 15, 2026 23:11 UTC | Nuvalent, Inc. NUVL · Entity 29892 | Disposition to issuerClass A Common Stock - Restricted Stock Units | 3,444 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-305095 · ownership.xml · nonDerivative · entry 2 Meyers Michael L. · CIK 0001664204 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F3 · kind: Each restricted stock unit represents a contingent right to receive one share of Class A Common Stock of the Company. F4 · kind: Pursuant to the Merger Agreement, each restricted stock unit that was subject solely to time-based vesting (a "Company RSU") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to (or deliverable under) such Company RSU immediately prior to the effective time of the Merger and (y) the Offer Price. F4 · shares: Pursuant to the Merger Agreement, each restricted stock unit that was subject solely to time-based vesting (a "Company RSU") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to (or deliverable under) such Company RSU immediately prior to the effective time of the Merger and (y) the Offer Price. F4 · price: Pursuant to the Merger Agreement, each restricted stock unit that was subject solely to time-based vesting (a "Company RSU") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to (or deliverable under) such Company RSU immediately prior to the effective time of the Merger and (y) the Offer Price. Read SEC document |
| July 15, 2026 Filed Jul 15, 2026 23:11 UTC | Nuvalent, Inc. NUVL · Entity 29892 | OtherClass A Common Stock | 5,146 | $124.00 | $638,104.00 |
DisclosureSEC source: 0001193125-26-305095 · ownership.xml · nonDerivative · entry 1 Meyers Michael L. · CIK 0001664204 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated June 9, 2026 (the "Merger Agreement"), by and among (i) Nuvalent, Inc., a Delaware corporation (the "Company"), (ii) GlaxoSmithKline LLC, a Delaware limited liability company ("Parent"), (iii) Harmony Row Acquisition Co., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"), and (iv) solely for purposes of Section 9.14 therein, GSK plc, a public limited company organized under the laws of England and Wales ("Ultimate Parent"), Purchaser completed a tender offer (the "Offer") to purchase all outstanding shares of Class A Common Stock of the Company and Class B Common Stock of the Company. The shares of Class A Common Stock of the Company and Class B Common Stock of the Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for $124.00 per share, net to the seller in cash, without interest (the "Offer Price"), subject to applicable withholding tax. F2 · kind: (Continued from footnote 1) After completion of the Offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. F1 · shares: Pursuant to the Agreement and Plan of Merger, dated June 9, 2026 (the "Merger Agreement"), by and among (i) Nuvalent, Inc., a Delaware corporation (the "Company"), (ii) GlaxoSmithKline LLC, a Delaware limited liability company ("Parent"), (iii) Harmony Row Acquisition Co., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"), and (iv) solely for purposes of Section 9.14 therein, GSK plc, a public limited company organized under the laws of England and Wales ("Ultimate Parent"), Purchaser completed a tender offer (the "Offer") to purchase all outstanding shares of Class A Common Stock of the Company and Class B Common Stock of the Company. The shares of Class A Common Stock of the Company and Class B Common Stock of the Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for $124.00 per share, net to the seller in cash, without interest (the "Offer Price"), subject to applicable withholding tax. F2 · shares: (Continued from footnote 1) After completion of the Offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. F1 · price: Pursuant to the Agreement and Plan of Merger, dated June 9, 2026 (the "Merger Agreement"), by and among (i) Nuvalent, Inc., a Delaware corporation (the "Company"), (ii) GlaxoSmithKline LLC, a Delaware limited liability company ("Parent"), (iii) Harmony Row Acquisition Co., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"), and (iv) solely for purposes of Section 9.14 therein, GSK plc, a public limited company organized under the laws of England and Wales ("Ultimate Parent"), Purchaser completed a tender offer (the "Offer") to purchase all outstanding shares of Class A Common Stock of the Company and Class B Common Stock of the Company. The shares of Class A Common Stock of the Company and Class B Common Stock of the Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for $124.00 per share, net to the seller in cash, without interest (the "Offer Price"), subject to applicable withholding tax. F2 · price: (Continued from footnote 1) After completion of the Offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. Read SEC document |
| June 16, 2026 Filed Jun 18, 2026 20:32 UTC | Nuvalent, Inc. NUVL · Entity 29892 | GrantClass A Common Stock | 3,444 | $0.00 | $0.00 |
DisclosureSEC source: 0001664204-26-000002 · ownership.xml · nonDerivative · entry 1 Meyers Michael L. · CIK 0001664204 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,590 F1 · shares: Consists of shares of Nuvalent, Inc. Class A Common Stock issuable under restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Nuvalent, Inc. Class A Common Stock. The RSUs vest in full on the earlier of June 16, 2027 or the date of Nuvalent, Inc.'s next annual meeting of stockholders, subject to continued service to Nuvalent, Inc. through the applicable vesting date. Read SEC document |
| June 18, 2025 Filed Jun 20, 2025 20:34 UTC | Nuvalent, Inc. NUVL · Entity 29892 | GrantStock Option (Right to Buy) · Derivative | 4,147 | $0.00 Strike: $75.53 | $0.00 |
DisclosureSEC source: 0000950170-25-088546 · ownership.xml · derivative · entry 2 Meyers Michael L. · CIK 0001664204 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,147 Underlying: Class A Common Stock · 4,147 shares Expires 2035-06-18 F2 · derivative.exercise_date: The shares underlying this option vest in full on the earlier of June 18, 2026 or the date of Nuvalent, Inc.'s next annual meeting of stockholders, subject to continued service to Nuvalent, Inc. through the applicable vesting date. Read SEC document |
| June 18, 2025 Filed Jun 20, 2025 20:34 UTC | Nuvalent, Inc. NUVL · Entity 29892 | GrantClass A Common Stock | 2,647 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-088546 · ownership.xml · nonDerivative · entry 1 Meyers Michael L. · CIK 0001664204 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,146 F1 · shares: Consists of shares of Nuvalent, Inc. Class A Common Stock issuable under restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Nuvalent, Inc. Class A Common Stock. The RSUs vest in full on the earlier of June 18, 2026 or the date of Nuvalent, Inc.'s next annual meeting of stockholders, subject to continued service to Nuvalent, Inc. through the applicable vesting date. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:10 UTC | Nuvalent, Inc. NUVL · Entity 29892 | GrantStock Option (Right to Buy) · Derivative | 3,789 | $0.00 Strike: $80.03 | $0.00 |
DisclosureSEC source: 0000950170-24-073653 · ownership.xml · derivative · entry 2 Meyers Michael L. · CIK 0001664204 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,789 Underlying: Class A Common Stock · 3,789 shares Expires 2034-06-12 F2 · derivative.exercise_date: The shares underlying this option vest in full on the earlier of June 12, 2025 or the date of Nuvalent, Inc.'s next annual meeting of stockholders, subject to continued service to Nuvalent, Inc. through the applicable vesting date. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:10 UTC | Nuvalent, Inc. NUVL · Entity 29892 | GrantClass A Common Stock | 2,499 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-073653 · ownership.xml · nonDerivative · entry 1 Meyers Michael L. · CIK 0001664204 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,499 F1 · shares: Consists of shares of Nuvalent, Inc. Class A Common Stock issuable under restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Nuvalent, Inc. Class A Common Stock. The RSUs vest in full on the earlier of June 12, 2025 or the date of Nuvalent, Inc.'s next annual meeting of stockholders, subject to continued service to Nuvalent, Inc. through the applicable vesting date. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 20:17 UTC | Nuvalent, Inc. NUVL · Entity 29892 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $44.68 | $0.00 |
DisclosureSEC source: 0001209191-23-037832 · doc4.xml · derivative · entry 1 Meyers Michael L. · CIK 0001664204 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Class A Common Stock · 15,000 shares Expires 2033-06-15 F1 · derivative.exercise_date: The shares underlying this option shall vest in full on the earlier of June 15, 2024 or the date of Nuvalent, Inc.'s next annual meeting of stockholders, subject to continued service to Nuvalent, Inc. through the applicable vesting date. Read SEC document |
| October 04, 2022 Filed Oct 6, 2022 20:30 UTC | Nuvalent, Inc. NUVL · Entity 29892 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $19.48 | $0.00 |
DisclosureSEC source: 0001209191-22-052987 · doc4.xml · derivative · entry 1 Meyers Michael L. · CIK 0001664204 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Class A Common Stock · 40,000 shares Expires 2032-10-04 F1 · derivative.exercise_date: The shares underlying this option vest over the next three years in equal monthly installments following October 4, 2022, subject to continued service to Nuvalent, Inc. through the applicable vesting date. Read SEC document |
| February 02, 2022 Filed Feb 3, 2022 22:31 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Options (Right to buy) · Derivative | 17,350 | $15.79 Strike: $15.79 | $273,956.50 |
DisclosureSEC source: 0001562180-22-001078 · primarydocument.xml · derivative · entry 2 Meyers Michael L. · CIK 0001664204 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,350 Underlying: Common Stock · 17,350 shares Expires 2032-02-02 F2 · derivative.exercise_date: 1/23rd of the shares subject to the option shall vest monthly over a two-year period. Read SEC document |
| January 31, 2022 Filed Feb 3, 2022 22:31 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | OtherCommon Stock | 1,714 | $12.39 | $21,236.46 |
DisclosureSEC source: 0001562180-22-001078 · primarydocument.xml · nonDerivative · entry 1 Meyers Michael L. · CIK 0001664204 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,280 F1 · kind: The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 1,715 shares by the Reporting Person on 1/31/22 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| December 30, 2021 Filed Jan 3, 2022 21:03 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 5,900 | $0.00 Strike: $8.77 | $0.00 |
DisclosureSEC source: 0001562180-22-000035 · primarydocument.xml · derivative · entry 2 Meyers Michael L. · CIK 0001664204 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,900 shares Expires 2027-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option is fully vested. Read SEC document |
| December 30, 2021 Filed Jan 3, 2022 21:03 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 5,900 | $8.77 | $51,743.00 |
DisclosureSEC source: 0001562180-22-000035 · primarydocument.xml · nonDerivative · entry 1 Meyers Michael L. · CIK 0001664204 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,566 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The Reporting Person is filing this Form 4 to report the acquisition of shares by the Reporting Person pursuant to the exercise of a stock option grant. There are no sales to report in this filing. Read SEC document |
| April 26, 2021 Filed Apr 28, 2021 20:15 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | PurchaseCommon Stock | 500 | $15.46 | $7,730.00 |
DisclosureSEC source: 0001562180-21-002976 · primarydocument.xml · nonDerivative · entry 1 Meyers Michael L. · CIK 0001664204 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,666 Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:21 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $21.36 | $0.00 |
DisclosureSEC source: 0001562180-21-000931 · primarydocument.xml · derivative · entry 3 Meyers Michael L. · CIK 0001664204 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2031-02-03 F3 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly over a four-year period. Read SEC document |
| January 31, 2021 Filed Feb 5, 2021 21:21 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | OtherCommon Stock | 1,771 | $12.00 | $21,252.00 |
DisclosureSEC source: 0001562180-21-000931 · primarydocument.xml · nonDerivative · entry 2 Meyers Michael L. · CIK 0001664204 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,166 F2 · kind: The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 1,771 shares by the Reporting Person on 01/31/2021 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| July 31, 2020 Filed Feb 5, 2021 21:21 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | OtherCommon Stock | 2,665 | $7.97 | $21,240.05 |
DisclosureSEC source: 0001562180-21-000931 · primarydocument.xml · nonDerivative · entry 1 Meyers Michael L. · CIK 0001664204 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,395 F1 · kind: The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 2,665 shares by the Reporting Person on 07/31/2020 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| July 06, 2020 Filed Jul 8, 2020 20:11 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantCommon Stock | 3,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-005074 · primarydocument.xml · nonDerivative · entry 1 Meyers Michael L. · CIK 0001664204 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,730 F1 · shares: 50% of the shares will vest on July 6, 2021 and the remaining 50% of the shares will vest on July 6, 2022. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 21:36 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Option (Right to Buy) · Derivative | 50,825 | $0.00 Strike: $9.47 | $0.00 |
DisclosureSEC source: 0001562180-20-001236 · primarydocument.xml · derivative · entry 1 Meyers Michael L. · CIK 0001664204 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,825 Underlying: Common Stock · 50,825 shares Expires 2030-02-12 F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly over a four-year period. Read SEC document |
| March 21, 2019 Filed Mar 22, 2019 20:05 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | PurchaseCommon Stock | 104 | $4.87 | $506.48 |
DisclosureSEC source: 0001562180-19-002012 · primarydocument.xml · nonDerivative · entry 2 Meyers Michael L. · CIK 0001664204 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,222 Read SEC document |
| March 21, 2019 Filed Mar 22, 2019 20:05 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | PurchaseCommon Stock | 1,000 | $4.93 | $4,930.00 |
DisclosureSEC source: 0001562180-19-002012 · primarydocument.xml · nonDerivative · entry 1 Meyers Michael L. · CIK 0001664204 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,118 Read SEC document |
| March 21, 2019 Filed Mar 25, 2019 20:03 UTC Amendment | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | PurchaseCommon Stock | 8 | $4.87 | $38.96 |
DisclosureSEC source: 0001562180-19-002023 · primarydocument.xml · nonDerivative · entry 1 Meyers Michael L. · CIK 0001664204 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,230 F1 · shares: Amendment filed to correct previously filed Form, which did not include 8 shares purchased in an additional transaction. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:27 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Option (Right to Buy) · Derivative | 104,325 | $0.00 Strike: $6.38 | $0.00 |
DisclosureSEC source: 0001562180-19-000853 · primarydocument.xml · derivative · entry 2 Meyers Michael L. · CIK 0001664204 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,325 Underlying: Common Stock · 104,325 shares Expires 2029-02-06 F2 · derivative.exercise_date: The securities awarded on 02/06/2019 were in the form of stock options issued pursuant to the Syndax Pharmaceuticals, Inc. 2015 Omnibus Incentive Plan. Options to purchase 50,825 shares of common stock shall vest in 48 successive equal monthly installments measured from 02/06/2019. Options to purchase 53,500 shares of common stock shall vest periodically upon the Issuer achieving certain milestones. Read SEC document |
| January 31, 2019 Filed Feb 8, 2019 21:27 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | OtherCommon Stock | 3,720 | $4.76 | $17,707.20 |
DisclosureSEC source: 0001562180-19-000853 · primarydocument.xml · nonDerivative · entry 1 Meyers Michael L. · CIK 0001664204 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,118 F1 · kind: The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 3,720 shares by the Reporting Person on 01/31/2019 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| October 30, 2018 Filed Nov 7, 2018 21:02 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | PurchaseCommon Stock | 200 | $4.79 | $958.00 |
DisclosureSEC source: 0001562180-18-004443 · primarydocument.xml · nonDerivative · entry 1 Meyers Michael L. · CIK 0001664204 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,398 F1 · balance_after: Includes 2,198 shares acquired under the Syndax Pharmaceuticals, Inc. 2015 Employee Stock Purchase Plan on 7/31/2018. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:04 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $9.40 | $0.00 |
DisclosureSEC source: 0001562180-18-001426 · primarydocument.xml · derivative · entry 1 Meyers Michael L. · CIK 0001664204 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2028-03-01 F1 · derivative.exercise_date: The stock option will vest in 48 successive equal monthly installments measured from February 8, 2018. Read SEC document |
| February 06, 2017 Filed Feb 8, 2017 19:13 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Option (Right to Buy) · Derivative | 66,100 | $0.00 Strike: $8.77 | $0.00 |
DisclosureSEC source: 0001562180-17-000568 · primarydocument.xml · derivative · entry 1 Meyers Michael L. · CIK 0001664204 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,100 Underlying: Common Stock · 66,100 shares Expires 2027-02-06 F1 · derivative.exercise_date: The stock option will vest in 48 successive equal monthly installments measured from February 6, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.